亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review

作者
Jianxiang Zhang,Lingyu Wang
出处
期刊:Technology in Cancer Research & Treatment [SAGE Publishing]
卷期号:18: 1533033819831068-1533033819831068 被引量:162
标识
DOI:10.1177/1533033819831068
摘要

T-cell receptor-engineered T-cell therapy and chimeric antigen receptor T-cell therapy are 2 types of adoptive T-cell therapy that genetically modify natural T cells to treat cancers. Although chimeric antigen receptor T-cell therapy has yielded remarkable efficacy for hematological malignancies of the B-cell lineages, most solid tumors fail to respond significantly to chimeric antigen receptor T cells. T-cell receptor-engineered T-cell therapy, on the other hand, has shown unprecedented promise in treating solid tumors and has attracted growing interest. In order to create an unbiased, comprehensive, and scientific report for this fast-moving field, we carefully analyzed all 84 clinical trials using T-cell receptor-engineered T-cell therapy and downloaded from ClinicalTrials.gov updated by June 11, 2018. Informative features and trends were observed in these clinical trials. The number of trials initiated each year is increasing as expected, but an interesting pattern is observed. NY-ESO-1, as the most targeted antigen type, is the target of 31 clinical trials; melanoma is the most targeted cancer type and is the target of 33 clinical trials. Novel antigens and underrepresented cancers remain to be targeted in future studies and clinical trials. Unlike chimeric antigen receptor T-cell therapy, only about 16% of the 84 clinical trials target against hematological malignancies, consistent with T-cell receptor-engineered T-cell therapy's high potential for solid tumors. Six pharma/biotech companies with novel T-cell receptor-engineered T-cell ideas and products were examined in this review. Multiple approaches have been utilized in these companies to increase the T-cell receptor's affinity and efficiency and to minimize cross-reactivity. The major challenges in the development of the T-cell receptor-engineered T-cell therapy due to tumor microenvironment were also discussed here.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英勇的兔子完成签到,获得积分20
刚刚
yongli1217完成签到,获得积分10
刚刚
棠臻完成签到 ,获得积分10
1秒前
1秒前
Soya_FERRUM完成签到,获得积分10
5秒前
科目三的应助被开心的秋柳采纳,获得10
6秒前
6秒前
乐乐的应助被赏光采纳,获得10
7秒前
淡淡山兰完成签到,获得积分10
8秒前
8秒前
一个西藏完成签到,获得积分10
9秒前
12秒前
12秒前
12秒前
坦率的枕头完成签到,获得积分10
12秒前
清爽的孤丝完成签到,获得积分10
13秒前
辛勤寻凝发布了新的文献求助30
15秒前
17秒前
18秒前
汉堡包的应助被高挑的橘子采纳,获得10
18秒前
LYDDDDD完成签到,获得积分10
18秒前
monair发布了新的文献求助10
19秒前
23秒前
熊猫奇思发布了新的文献求助10
25秒前
科研通AI6.4的应助被伯赏诗霜采纳,获得10
25秒前
26秒前
27秒前
伶俐的秀发完成签到,获得积分10
28秒前
xxx完成签到 ,获得积分10
30秒前
赏光发布了新的文献求助10
32秒前
zeee发布了新的文献求助10
32秒前
所所的应助被熊猫奇思采纳,获得10
32秒前
34秒前
36秒前
38秒前
赏光完成签到,获得积分10
38秒前
归迟完成签到,获得积分10
40秒前
Gtanya完成签到 ,获得积分10
41秒前
TD发布了新的文献求助10
42秒前
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194990
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872527
捐赠科研通 7794694
什么是DOI,文献DOI怎么找? 3437819
关于科研通互助平台的介绍 2561149
邀请新用户注册赠送积分活动 2484526